# A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)

> **NCT00989001** · PHASE3 · TERMINATED · sponsor: **Advanz Pharma** · enrollment: 217 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Vernakalant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00989001
- **Lead sponsor:** Advanz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2014-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989001, "A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00989001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*